Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Oncology 48

Oncology

Agios' cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Agios’ cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial

Servier Acquires Agios' Cancer Portfolio in a USD 2 Billion Deal The year is a prime witness of pricey deals and acquisitions in the pharmaceutical industry. To leave its mark, another player decided to hop onto the list. French drugmaker Servier has announced the acquisition of the Oncology business of Agios Pharmaceutical in a deal worth USD 2 billion. Parceled in the deal, besides Agios' co-commercialization responsibilities for Bristol Myers Squibb's Idhifa (enasidenib), Servier announced, are Agios’ oral leukemia treatment Tibsovo, vorasidenib, AG-270, and AG-636. Tibsovo approved for relapsed or refractory acute myeloid leukemia (R/R AML) with a susc...

Explore More...

Sygnis AG and ECACC Collaboration; BioNTech and Genentech Partnership; Partnership between Zydus Cadila and Takeda; Global Agreement between Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical

PI3Kγ- a molecular switch that controls immune suppression

HER2 Expression and its Dynamic Functional States

Novel Genetics Biomarker found by a Group of Researchers May Offer Novel Treatment Approach for Cancer

Sun Pharma forms partnership; Pfizer and DCRI collaborate; Avara Acquires AZ; ASLAN Pharmaceutical’s Collaboration; Amgen and Servier partnership

Treatment for esophageal cancer; FDA bans soaps; Dr Reddy’s Launches; Cipla Gets Approval

Recent Pharma Developments related to Immune Checkpoint Activators

Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys; Insys marketed drug

Identity Crises Faced by a Venerable Brain-Cancer Cell Line

Default Blog Image

PD-1 and PDL-1 Immune Check Point Inhibitors: A Prodigious Revolution in Cancer Treatment

Bristol Meyers Squibb & AbbVie partner; BioLineRx’s collaboration with MD Anderson Cancer Centre; Partnership between Regeneron Pharmaceuticals and Adicet Bio; Immunotherapy Target Unique Mutations in cancer

The Curious Case of CRISPR Technology

Lupin acquired; FDA grants approval; NATCO gets approval; Wockhardt Ltd. gets import alert; Patent fight

Collaboration provides new insight into cancer treatment

Default Blog Image

Pharm Delve Cognizance

Turning your own skin cells into cancer-killing machines

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly